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1  Introduction and Background
1.1  Historical Notes
Hepatitis E (HEV), the causative agent of what has been referred to as enterically transmitted
non-A, non-B hepatitis or ´waterborne hepatitis´, is a major cause of epidemic and acute
sporadic hepatitis in developing countries (Khuroo et al., 1980; Bradley et al, 1990;
Mushawar et al., 1997).The disease was first recognized  as distinct, clinical entity in the
1980´s when the sera from persons affected during a large waterborne epidemic of viral
hepatitis during 1956-56 in New Delhi, India and another epidemics in Kashmir were found to
lack serological markers of acute hepatitis A and B .(Viswanathan et al., 1957;Khuroo et al.,
1980). The occurrence of the first recorded epidemic of hepatitis E as late as 1955 and the
frequency of this disease suggest that hepatitis E is a new, emerging infectious disease. The
first proof of the existence of a new viral hepatitis agent was obtained in 1983, when virus-like
particles were detected by immune electron microscopy in the faeces collected from a
volunteer who was infected with faecal material from patients with suspected enterically
transmitted non-A, non-Bhepatitis. (Balayan et al., 1983). Outbreaks of HEV infections have
occurred in a number of countries in Africa, Asia as well as in Mexico, and are usually
associated with warm weather and poor sanitation leading to faecal contamination of drinking
water. Sporadic cases can also occur in areas where HEV is endemic, usually during periods
between major outbreaks. Sporadic cases have been also reported in areas not considered
to be endemic for HEV. Many of these can be associated with travellers returning from visits
to areas where HEV is endemic. There have been reports, however, of HEV-associated
hepatitis among individuals with no history of travel to regions endemic for HEV ( Zaijer et al.,
1993; Zannetti et al., 1994). It was generally believed that such occurrences are rare in
developed nations.
The genome of the agent was originally identified and characterized using cynomoglus
macaques infected experimentally with human faeces obtained from patients during an
outbreak in Burma (Reyes et al.,1990).  A second isolate was similarly identified from an
outbreak that had occurred in Mexico. These first two prototype isolates of HEV were similar
in overall genomic organization but still distinct from each other having 76% identity over theHepatitis E - Virus (HEV):
Comparative evaluation of IgG antibody assays in a low-endemicity setting
Page 8
entire genome comprised of three discontinuous open- reading frames (ORF´s) (Huang et al.,
1992). In the years immediately after the identification of the Burmese and Mexican prototype
viruses, a number of additional isolates were identified from Pakistan, India and China..
Interestingly, all of these isolates were related very closely to the original isolate from Burma
having a greater than 93% nucleotide identity across the genomes. At that time, the genotypic
distribution of HEV consisted of a group of Burmese-like and the lone Mexican isolate.
The first indication that additional genetic diversity may occur in regions non-endemic for HEV
was the identification of a distinct endogenous variant identified in an acute hepatitis patient
from United States (US) who reported  no recent travel history to endemic regions (Schlauder
et al., 1996; Kwo et al.,1997). Additional sequencing of the full-length genome of this and the
isolate confirmed that a new group of HEV did exist that was distinct from the Burmese-like
and Mexican isolates (Schlauder et al., 1998; Erker et al., 1999).
The discovery of the human US strains of HEV led to the identification of a number of
additional isolates from other non-endemic regions using primers based on the sequence
from the first human US isolate. Patients from Italy and Greece were identified who were
infected with variants of HEV that were quite distinct from the original isolates from Burma
and Mexico, as well as the those from US (Psichogiou et al., 1995; Schlauder et al., 1999;
Zanetti et al., 1999). These variants were related most closely to the US isolates, however,
they were not subtypes of the US group. In fact, they were found to represent three new groups
of HEV.
Although there appeared to be a geographical distribution of genotypes up to this time (fig.1),
the identification of the two distinct isolates from Greece indicated that there could be
significant diversity between strains from the same region. Recently, isolates from patients
from Argentina and Austria have been identified and  are distinct from each other as well as
all previously identified isolates (Worms et al., 1998; Schlauder et al., 2000). Most recently ,
two isolates from patients from Spain  have been identified and were reported to be related
most closely to one of the Greek isolates (Pina et al., 2000). Extensive diversity has also be
reported between HEV strains from a number of patients from China and Taiwan that are
distinct from the original Chinese isolates, which are closely related to the Burmese isolates
(Wang et al. 2002; Norder et al., 2002).Hepatitis E - Virus (HEV):
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The possibility of zoonotic infections from pigs to humans was initially indicated after the
experimental infection of pigs with human strain of HEV (Balayan et al.,1990) The
identification of antibodies to HEV in domestics farm animals in Thailand, and the
identification of HEV RNA and HEV-like sequences in swine from China, New Zealand,
Thailand, and the US, support this possibility (Clayson et al., 1996;  Meng et al., 1997;
Garkawenko et al., 2000; Haqshenas et al., 2002). In addition, HEV RNA very similar to the
isolates identified in patients from Spain  was also detected in swine slaughterhouse sewage
(Pina et al., 2000). The observation that the Chinese and US isolates are almost closely
related to the human viruses from those regions suggests that human and swine HEV may co-
exist in several different geographical regions. These results were highly suggestive that HEV
infection could be a zoonotic, although no direct evidence has yet been demonstrated
(Haqshenas et al., 2002; Norder et al., 2002).Hepatitis E - Virus (HEV):
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Figure 1. Phylogentic relationships between hepatitis E virus isolates Nucleotide sequences
encoding the structural regions (Open Reading Frame ORF2 and ORF3 of selected hepatitis
E virus (HEV) isolates from different geographic locales were subjected to phlylogenetic
analysis by S. Jameel Expert Reviews in Molecular Medicine 1999; Cambridge University
Press.Hepatitis E - Virus (HEV):
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1.2  The Genome of the Hepatitis E Virus (HEV)
After successful transmission of Virus like particles (VLP´s) to non human primates and by
using bile (Bradley et al., 1994) as source of VLP´s for cloning of the viral genome, the virus
was finally characterized and named hepatitis E virus. The cloning of HEV was followed by the
sequencing of its genome. Sequencing of four distinct isolates of HEV including those from
Burma, Mexico, Pakistan and China (Yarbough et al., 1991) has already been completed. A
partial HEV genome sequence has been identified in a strain from Kirgizstan and Uzbekistan
(Yarbough et al., 1991).
Molecular analysis of the HEV genome has shown that it is a positive single-stranded RNA of
a about 7.5kb in length with short 5´- and 3´-noncoding regions which contain three separate
open reading frames (ORF´s) and very small variations among isolates (Purdy et al., 1993).
Minor sequence divergence was noted between Asian and Mexican isolates. The main
features of the HEV genome are as follow;
The putative non structural genes at end of the genome.ORF1 is located at the  5´end and the
structural genes are located at the 3´end of the genome (Fig 2). ORF1 is located at the 5´end
(5kb), it begins 28 nt away from the 5´end, extends 5.079 bp , ends at the 5,107 nt and
encodes for non structural proteins. The ORF2 is located at the 3´end, begins at 5,147 nt,
extends 1,980 bp, terminates 65 bp upstream of the poly (A) tail and encodes for structural
proteins. The ORF3, the smallest one, is located at the end of ORF1, encompasses 369 bp
overlaps the first ORF1 at its 5´end by 1 nt, significantly overlaps ORF2 and encodes a
protein of an unknown function(s).
The 5´untranslated region (28bp) possibly plays a role in transcription of the virus. Analysis of
the nucleotide sequence of the Burmese isolate reveals the presence of consensus
sequences in ORF1 (putative non structural gene) encoding;Hepatitis E - Virus (HEV):
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a)  An RNA-dependent RNA polymerase located at the extreme carboxy-terminal portion
of the ORF1 polyprotein.
b)  An RNA helicase (seen in all other geographically distinct isolates).
c)  A methyl transferase, located at the amino-terminal of the polyproteins, suggesting that
HEV is capped.
d)  An Ý ´domain of unknown function.
e)  A putative papain-like cystein protease domain.
f)  An ´X´ domain of unknown function, acting as a flexible hinge
(Bradley et al., 1991).
Figure 2: The genetic structure of HEV Virus (Yarbough et al, 1999)Hepatitis E - Virus (HEV):
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ORF2 encodes major structural proteins comprising a glycosylated protein (660aa) used in
transport, major immunological epitopes  and  a polypeptide with a high percentage of basic
amino acids ( Jamell et al., 1996). ORF3 encodes a protein (123aa) with an immunoreactive
epitope at the carboxy –terminus and a transmembrane sequence at the amino-terminus.
HEV appears to be substantially different from picorna viruses including HAV (Bradley et al.,
1991). Based on hybridisation experiments, IEM and immuneflourescence blocking studies, it
was indicated that a single major agent is responsible of ET-NANBH cases worldwide
(Bradley et al., 1991). A comparison of parts of the sequences of the ORF2 regions of HEV
cDNA demonstrated that the nucleotide sequence homology is 95.7% among the four
Chinese strains of HEV. The amino acid sequence identity ranged from 95.4 to 98.5% The
homology of the nucleotide and the amino acid sequence of the ORF2  regions between the
four Chinese HEV strains and the Burma strain (92.3 to 94.5% and 96.2 to 97.7%,
respectively) was much higher than the Mexico strain (79.3 to 80.2% and 88.8 to 93.9%,
respectively). Thus, all four Chinese strains showed a higher degree of nucleotide sequence
homology compared to the Burma and Mexico strain, suggesting that HEV subtypes may be
associated with different geographical location (Yarbough et al., 1999).Hepatitis E - Virus (HEV):
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1.3  Genetic Heterogeniety
The genome sequence of HEV seems to relatively stable. The nucleotide identity of strains
isolated in a single outbreak is high and serial passages in cynomolgus monkeys do not
results in a genetic drift. Substantial genetic diversity one isolate in comparison to others from
the same outbreak probably represents the sporadic cases of hepatitis E (Arankalle et al,
1999).
The genome of strains isolated from geographically distinct locations is generally more
diverse. The full-length overall nucleic acid identity of two prototype strains Myanmar and
Mexico. However, the deduced amino acid identity is 84%, 93% and 87% for ORF1, ORF 2
and ORF 3, respectively (Takahahi et al, 2003). Most of the nucleotide substations are
conservative and only hypervariable sequences of ORF1 result in substantial aminoacids
diversity. No evidence has been found that serological heterogeneity results from the genetic
diversity, thus HEV seems to exist as a single serotype.
As present, no consensus exists on genotype classification of HEV and the same holds true
for antigenic classification. Currently, the detected HEV strains are genetically characterized
in laboratories on the basis of ORF1 and 2 as well as ORF 3 regions. In addition, some
research workers started to antibodies produced by recombinant-expressed capsid proteins
(Wang et al., 2001). Genetically distinct strains may turn out to have serologically surface-
exposed epitopes. Strains isolated in endemic regions can be classified into genotype (
strain from Asia and Africa). Genotype II would be the Mexican-type group. Besides strains
from Mexico, this group from Nigeria (Schlauder et al, 2001). Strains detected in cases of
acute HEV infection in the US, in parts of Europe (Italy, Greece, Spain) and Argentina show a
relatively high degree of diversity (> 20%) to strains from endemic areas, and would genotype
III strains. Genotype IV consist of recently detected Chinese isolates. Sequences of ORF 1
fragments indicates that Taiwanese isolates may be a part of this group (Shlauder et al,
2001).Hepatitis E - Virus (HEV):
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In addition, novel strains have been isolated in pigs (Purcell et al, 2000). Some swine HEV
isolated showed  a close genetic relatedness between the genotype III humans strains and
swine strains isolated in the same area (Hsieh et al, 1999). Both the human and the swine
isolates , can cross species barriers. This was demonstrated by infecting primates, rats and
swine with human HEV isolates and primates with human isolates (Takahashi et al 2003,
Meng et al, 1998).Hepatitis E - Virus (HEV):
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1.4  Cell Culture
The replication strategy of the HEV is poorly understood. Several strategies for experimental
propagation and production of HEV to study the molecular biology and facilitate vaccine
development have been published, but their reproducibility and feasibility need confirmation
(Clemente-Casares et al, 2003).
A recent in vivo cell culture experiment used in vivo infected highly differentiated primate liver
cells for the in vitro replication of HEV in a serum-free medium supplemented with growth
factors  and hormones. A strand-specific RT-PCR technique was used for monitoring.(Worm
et al , 2002) Both positive strand and negative-strand HEV RNA were detected in cellular
RNA of the culture cells and the positive-strand HEV RNA was detected in the culture medium
(indicating shedding of virus-like particles into the culture medium).No cytopathic effects were
observed. Thereafter, using the identical culture system, primary hepatocytes were infected
with non-inactivated tissue culture-derived viruses and replication of REV RNA was
demonstrated in this model. A neutralizing anti-HEV antibody directed against the ORF-2
encoded putative capsid protein blocked the infection of the liver cells (Yarbough et al, 1999).
New Chinese strains of HEV have been isolated and cultivated in an in vitro cell culture using
continuous cell lines derived from the lung, kidney, or liver. Recently, a Chinese HEV isolate
was successfully cultivated in a A549 cells (human lung carcinoma cells) under the conditions
of a relatively high concentration of MgCl2 (30 mM), a pH of 7.2, and a short (< 6 months)
preservation time of propagated strains. Cytopathic effects (cell rounding and mono layer
destruction) were visible at day 2 post-inoculation and could be neutralized by specific acute-
phase antibodies to HEV (Huang et al, 1999).Hepatitis E - Virus (HEV):
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1.5  Stages of Replication
Because evidence for propagation of HEV in cell culture is quite limited(Huang et al .
1992), and because HEV is not closely related to any other well- characterized virus, little
is known about its strategy for replication. The mechanism of attachment, entry, and
uncoating of HEV is unknown but assumed that the virus attaches to receptor sites on the
hepatocytes and possibly cells in the intestine. After uncoating, the 7,5-kb genome is
probably translated via cellular mechanisms that recognize capped RNA. Cleavage of
translated ORF-1 is likely achieved by cellular proteases.  The motif of a papain-like
protease has been detected in the sequence ORF-1 (Koonin et al., 1993), but it is not
known whether it is functional. Replicative intermediate negative-stranded RNA is
probably synthesized by the viral polymerase, as are subsequent strands of positive sense
full-length (genomic and messenger) RNA, as well as at least two subgenomic  and co-
terminal messenger RNAs, 3,7 and 2,0-kb in size, respectively(Tam  et al.,1991). Nothing
is known about assembly and transport. The gene products of both ORF-2 and ORF-3
contain hydrophobic signal-like sequences at their 5 ´ends but it is not  known whether
they have a  function  (Reyes GR et al.,1991). Nothing is known about release of the virus
from infected cells.Hepatitis E - Virus (HEV):
Comparative evaluation of IgG antibody assays in a low-endemicity setting
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Figure 4. A proposed model of hepatitis E virus replication.
This model is based on domain homologies between hepatitis E virus (HEV) and other
positive-stranded RNA viruses. (a) Following attachment to an as-yet-uncharacterised
receptor on the surface of hepatocytes, HEV is internalised and uncoated in the cytoplasm
by unknown mechanism. (b) The genomic positive-strand RNA is translated into nsP, theHepatitis E - Virus (HEV):
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non structural polyprotein encoded by ORF1, which can be  processed into individual
functional units that might  include methyltransferase, protease, helicase and replicase
activities. (c) The replicase so generated can use the positive-strand RNA as templates to
synthesise the negative strand replicative intermediates. Because  of homology to
alphaviral junction sequence (shown as boxed region on the negative-strand RNA), it is
proposed the two classes of positive-strand  RNA species, genomic (d) and
subgenomic(e), are synthesised from  the negative-strand RNA intermediates. (f) The
genomic RNAs are translated into pORF2 viral structural proteins encoded by ORF2 (and
possibly pORF3 encoded by ORF3 ).Hepatitis E - Virus (HEV): 
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1.6  Pathogenesis and Pathology 
Because serologic and molecular tests for HEV were developed only recently, the 
pathogenesis of hepatitis E is poorly understood. However, some speculative conclusions 
can be drawn. Entry of the virus into the host is believed to be primarily by  the oral route 
via contaminated water. The site of primary replication has not been identified but is 
presumed to be intestinal tract. It is not clear how the virus reaches the liver but it is 
presumably via the portal vein. It replicates in the cytoplasm of hepatocytes (Bradley et al  
1991) and is released into the bile and the blood by mechanisms  that are not understood. 
Based upon limited studies of oral infection in a volunteer,  viremia was first detected by 
PCR 22 days after exposure and over a week before onset of disease on 30 days 
(Chauhan et al., 1992). Virus particles were found by IEM in the faeces by 34 days after 
exposure .Liver enzyme values peaked on day 46. Anti-HEV was first detected on day 41 
and was still detectable 2 years later. Similarly, in another, earlier volunteer study, HEV 
was detected in faeces by IEM on the day 28, and liver enzyme levels peaked on a 
approximately day 4 .(Balayan  et al 1983). The individual volunteers in each of the studies 
recovered completely. As in hepatitis A, specific IgM and IgG immune responses occur 
early in the disease, usually by onset of clinical illness. I gM anti-HEV disappears after 
several months; IgG anti-HEV persists , but at a relatively rapidly decreasing levels shortly 
after infection ( half-life of IgG anti-HEV;< 6 months) (Bryan  et al.,1994). Later, the decay 
of anti-HEV is less rapid but it  is  still considerably more rapid than that of anti-HAV. 
Nevertheless, anti-HEV can be detected for as long as 14 years after infection (Khuroo et 
al., 1993). It is not  known whether such antibody eventually disappears or remains at low 
but detectable levels. Anti-HEV of the IgA class has also been detected in the serum of 
naturally infected individuals (Dawson GJ et al 1990).  The significant of such antibody is 
not known. Virus found in the faeces of the individuals is presumed to be primary source of 
infectious virus in the environment. Because large quantities of HEV have been found in 
the bile of experimentally infected primates, it is assumed the bulk of virus in the intestinal 
tract originates in the liver (Reyes et al., 1990). In this respect, hepatitis E is similar to 
hepatitis A. The severity of HEV infections is, on average somewhat greater than the 
severity of HAV infections. Mortality of hepatitis E has varied in different reports bit has 
been as high as 1%, compared to 0,2% for hepatitis A (Purcell et al., 1989). More Hepatitis E - Virus (HEV): 
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important, however, is the of hepatitis E in pregnancy increases with each succeeding 
trimester and my reach 20%. In contrast, none of the other four recognized hepatitis 
viruses causes such severe hepatitis in pregnancy (Mishra et. al 1992). The reason for the 
excessive mortality of hepatitis E in pregnancy is unknown. Fulminant NANB hepatitis 
occurring in non-endemic areas not to be caused  by HEV (Kuwada  et al.,1994). 
Histological changes in the liver of patients with hepatitis are thought by some to be 
characteristic (Purcell et al.,1982). The changes include focal necrosis with minimal 
infiltration and no localization to a particular zone of the lobule. Modest inflammation 
consisting predominantly of Kupffer cells and the polymorphnuclear leukocytes is seen and 
the focal lesions resembles drug-associated toxic hepatitis. Cholestatic hepatitis is often 
present is often, characterized by ballooning hepatocytes, cytoplasmic cholestasis , and 
the focal cytolytic necrosis. An unusual “pseudoglandular” alteration of the hepatocyte 
plates has been recognized in some epidemics. The pathogenesis of fulminant hepatitis E 
of pregnancy was though by the late Hans Popper to be a manifestation of endotoxin –
mediate release of toxic cytokines as the result of damage to Kupffer cells, the main 
protection of hepatocytes from toxins generated in the intestinal tract (Purcell et al.,1982). 
The discrepancy between the time of appearance of viral replication in the liver and 
histopathologic and biological evidence of hepatitis suggest that HEV is not cytopathic 
and that the pathogenesis of hepatitis E is immunologically mediated, but there is no 
direct evidence for or against this hypothesis(Soe et al.1989) . It is  not known whether 
HEV causes sequelae or extrahepatic manifestation  of infections. None has been 
recognized , except for excess  fetal  wastage, which has been reported in some (Malkani  
et.al.l1992), but not  all , studies of pregnant females with fulminant hepatitis E. Premature 
deliveries with a high infant mortality (33%) have  also been reported (Song D-Y et al., 
1991). Hepatitis E - Virus (HEV): 
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1.7  Epidemiology 
 
Figure: 3 Geographic distribution of the Hepatitis E Virus 
Hepatitis E virus infection is endemic in Southeast and Central Asia. Several outbreaks of 
hepatitis E  have been observed in the Middle East, northern and western parts of Africa 
and North America (Mexico),  Fig: 3) (Krawczynski K. Hepatology 1993;17 923-41). 
 In other parts of the world, HEV infection is infrequent and restricted  predominately to 
persons who have travelled to disease-endemic areas. Hepatitis E outbreaks are large, 
affect several hundred to several thousand persons, and vary from short-lived, single-
peaked outbreaks to prolonged, multimodal epidemics lasting for more than a year 
.(Vishwanathan R. Indian J. Med. 1957;45:1-29). During these  outbreaks, overall attack 
rates range fro 1 to 15%, being higher among adults (3 to 30%) than among children (0,2 
to 10%) (Khuroo et al,. 1980). The lower attack of children may reflect a higher frequency 
of anicteric and / or subclinical HEV infection in this age group. Males are usually more 
frequently affected. The outbreaks are characterized by a particularly high rate and 
mortality(as high as 25%) among pregnant women (Naik SR Bull. WHO 1992; 70;597-
604) In areas where hepatitis E outbreaks occur, HEV account for a substantial proportion 
of acute sporadic hepatitis in both children and adults. In India, HEV infection accounts for 
50 to 70% of all sporadic viral hepatitis (Khuroo et al., 1993;) Demographic and clinical 
features of patterns with sporadic hepatitis E resembles of those patients with epidemic 
hepatitis E Sporadic hepatitis E has been observed in several countries where outbreaks Hepatitis E - Virus (HEV): 
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have been not  reported, including Egypt, Hong Kong, Senegal and Turkey. In non-
endemic regions, the disease accounts for fewer than 1% of reported cases of acute viral 
hepatitis; these hepatitis E cases are almost associated with travel to endemic-regions 
(CDC Weekly Rep.1993;42;1-4), although some cases have b een reported among 
persons with no history of such travel (Dawson et al.,1994). In the United States, all cases 
of HEV infection have been related to disease-endemic countries until recently, when HEV 
infection was reported in a patient without such a travel history (Dawson GJ et al., 1998). 
Molecular study have shown that the patient was infected with the novel HEV isolate (HEV 
US-1). 
 Hepatitis E - Virus (HEV): 
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1.8  Transmission, Routes of Spread and Reservoirs 
The faecal-oral route is the predominant mode of transmission of epidemic HEV infection. 
Most reported epidemics have been shown to be related to consumption of faecally 
contaminated drinking water. (Khuroo et al., 1980). The outbreaks frequently follow  heavy 
rains and floods, when water sources have become  contaminated. (Bradley  et al.,1984 ). 
Some epidemics have occurred in hot summer months , when the reduction of water flow 
in  rivers and streams may  contribute to an high risk of infection (Corwin A et al.,1995). In 
Indian subcontinent, China Indonesia and Central Asia republics of the  former Soviet 
Union, a pattern of recurrent epidemics has been observed, this is probably related to 
continuous existence of conditions that that allow faecal contamination of water. During 
hepatitis E outbreaks, person to person transmission  of HEV appears to be distinctly 
uncommon (Aggrawal et al.,1994;). Secondary attack rates among household members of 
hepatitis E cases are only 0,7-2,2%; in contrast, 50-75%, of susceptible household 
contact of hepatitis A cases known to become infected (Anderson et al., 1982). Even 
when such multiple cases occur among members of a family, such occurrence is related to 
exposure to a common source of contaminated water rather than person to person spread  
(Naik et al., 1994). The mode of transmission responsible for sporadic HEV infection is 
unclear. Water contamination appears to be responsible for most  cases in this setting.It is 
however, plausible that food and fomites, and even person to person may play a role. 
Nosocomial spread of HEV was presumed to be responsible for acute hepatitis in three 
health- care  workers in South Africa who  had treated a patient with fulminant  hepatic 
failure due to HEV infection (Robson SC et al.,1992). 
The reason of transmission patterns of hepatitis A and HEV are presently unclear but may 
relate to difference in viral titres in stools of infected persons,  number of viral particles 
required to cause disease, or viability of these viruses in the environment. Vertical 
transmission  of HEV infection from mother to infants is known to occur. One study, six of 
eight babies born to mothers who had either acute uncomplicated hepatitis or fulminant 
hepatic failure from HEV infection in the third trimester of pregnancy were found to have 
evidence of HEV infection (Khuroo et al 1.,995). Of these six  babies, five had  HEV-RNA 
in their cord blood ; another one baby had serological evidence of HEV infection acquired Hepatitis E - Virus (HEV): 
Comparative evaluation of IgG antibody assays in a low-endemicity setting 
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before birth. There is no evidence of sexual transmission of HEV, although in a report from 
Italy , 20% of homosexual men had anti-HEV antibodies as compared with only 3% of 
intravenous drug users (Psichogiou et al.,1996), thus suggesting faecal-oral transmission 
of HEV. There is no evidence serological  for transmission of HEV by transfusion of blood 
or blood products, however, serological tests used by Thomas and colleagues (Thomas et 
al, 1997) have reported that anti-HEV is detected in about 21% of blood donors and 23% 
of injection drug users from Baltimore, Maryland. In Northern California, about 1.2 to 1.4% 
of blood donors are found to be anti-HEV positive. Similar results have been reported in 
other industrialized countries including the Netherlands, Italy Sweden, Germany, Greece, 
England, Finland, Spain and Taiwan (Peng, CT et al, 2002). However, it should be 
remembered that the specificity and the sensitivity of these ´´ in house´´ anti-HEV 
serological assays are unknown, though some anti-HEV assays validated with serial 
serum samples from animals experimentally infected with different HEV strains (Xiang-Jin 
et al 2002). Furthermore,  anti-HEV antibody prevalence rates among patients with 
haemophilia and thalassaemia and intravenous drug users are similar to those for general 
population (Schulman S JMV 1995;46;153-6). Presumably, an environment reservoir of 
HEV exist in disease-endemic areas that is responsible for recurrent epidemics. 
Laboratory investigations have shown, however, that HEV is labile virus when exposed to 
high concentration of salt, freeze-thawing and pelleting  (Bradleyet al.,.1992). Another 
potential r eservoir for persistence of HEV during interepidemic periods in disease-
endemic areas may be in the form of serial transmission among susceptible individuals 
who have sporadic or subclinical hepatitis E. Recent data suggest that the hepatitis E may 
be zoonotic disease. Hepatitis E virus- RNA has been detected in faeces of domestic 
swine in Nepal and anti-HEV antibodies have been detected in sera of pigs, cattle, sheep 
and rodent in disease-endemic areas .(Clayson et al.,.1995). Pigs and lambs have been 
shown to develop transaminasaemia, histological changes in the liver and viral excretion  
in faeces after experimental HEV infection (Usmanov et al., .1994) In addition, a novel of 
strain of HEV, a swine HEV has recently been identified and shown to be ubiquitous in the 
USA. Antibodies to swine HEV cross- reacted with human capsid proteins from human 
strains of HEV. (Pilar, C et al 2003). Swine in  USA become infected by swine HEV at 
about two to three months of age. Although the infection is subclinical, microscopic 
evidence of hepatitis has been found in naturally infected swine (Xian-Jin et al, 2002).HEV Hepatitis E - Virus (HEV): 
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infection in swine is likely to be common worldwide. Recently the prevalence of anti-HEV 
IgG in swine was assessed in two countries where HEV is endemic (China and Taiwan) 
and the two countries where it is non-endemic (Canada and Korea) (Tsutomu, N et al 
2003). It was found that swine herds in all four countries  contain many  swine that are 
seropositive for HEV, suggesting that HEV is enzootic in swine regardless of whether 
HEV is endemic in the respective human population (Masaharu, T et al, 2003).  As refer to 
above, a US  isolate of HEV and swine HEV have been shown to be phylogenetically 
related and to posses cross species infectively, leading to further support to the zoonotic 
hypothesis (Meng et al, 1998). Hepatitis E - Virus (HEV): 
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Figure 4. Time of course of hepatitis E virus infection. 
Biochemical markers (e.g serum ALT levels) and symptomatic markers (e.g. jaundice) of 
viral hepatitis are correlated with detection of HEV RNA by TR_PCR in the bloodstream, 
or shedding of virus in stools, and the immune response is measured as anti-HEV IgM or 
IgG levels, detected by enzyme immunoassay on serum samples. Four to eight weeks 
after exposure to HEV, there is  a rise in ALT and the appearance of jaundice.. 
Immediately prior to the onset of clinical symptoms, HEV can be detected in the 
bloodstream, but continues to be shed  in stools for 3-4 weeks. At the onset of  clinical 
symptoms, HEV is lost from bloodstream, but continues to be shed in stools. Anti-HEV 
IgM and IgG titires continue to increase in the asymptomatic phase.  
The anti-HEV IgM titire peaks during the symptomatic phase and  declines thereafter to 
baseline within 3-6 months of symptomatic disease. The anti-HEV IgG remains detectable 
for 2-13 years as determined in various studies (Modified from the viral hepatitis slide set 
published by the US Centres for Control, Atlanta, GA, USA).  Hepatitis E - Virus (HEV): 
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1.9  Hepatitis E in Pregnancy 
One distinctive clinical  feature of hepatitis E, compared with other forms of viral hepatitis, 
is its increased incident and severity in pregnant women (Khuroo MS et al1994), which 
results in up to 20% mortality. By contrast, none of the other hepatitis viruses causes such 
severe hepatitis in pregnancy. Though the mechanism(s) is not known, a hypothesis has 
been put forward to explain the pathogenesis of fulminant  hepatitis E in pregnancy 
(Purcell RH et al Allan Liss Press N.Y USA). This suggests that the liver sinusoidal cells, 
particularly the Kupffer cells, are damaged by HEV, which diminishes the ability of these 
cells to protect hepatocytes against endotoxins that originate from Gram-negative bacteria 
found in the intestinal tract. Hepatocytes can be injured directly by endotoxins or indirectly 
intravasal coagulation affecting the liver and kidneys. In pregnant women, a high incidence 
of disseminated intravascular  coagulation associated with hepatitis E is well recognised. 
However, in experimental HEV infection of pregnant monkeys, no increased mortality has 
been observed, casting doubt on whether this is a good model for this aspect  of human 
hepatitis E. Liver histology of patients with hepatitis E reveals portal triaditis, chlolestasis, 
lobular inflammation and degeneration of the liver to varying degrees, which are 
suggestive of acute viral hepatitis. However, nearly half of the patients have distinctive 
morphological changes designated as  cholestatic viral hepatitis. The discrepancy 
between the time of appearance of viral replication in the liver with the histopathological 
and biochemical changes suggest that HEV might not be directly cytopathic and its 
pathogenesis might be immunologically mediated. However, there is no direct evidence 
for, or against, this hypothesis (Purcell Rh et al 1998). It is not known whether HEV causes 
other sequelae or extrahepatic manifestations. None has been recognised apart from the 
increased incidence of  miscarriage, which has been reported in some, but not all, studies 
on fulminant hepatitis E during pregnancy.  Hepatitis E - Virus (HEV): 
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1.10  Diagnosis and Seroprevelance Data 
The prevalence of anti-HEV in healthy subjects has been studied in various population 
worldwide to measure the extent of exposure to HEV. It has been found that anti-HEV 
antibodies are present in persons living in all geographical areas. In disease-endemic 
areas of Asia and Africa, the prevalence rates among healthy populations are much higher 
than those in non-endemic areas. In most disease-endemic areas, anti-HEV has been 
detected in as many as 5% of children less than 10 years of age, and this ratio increases 
to 10-40% among adults older than 25 years of age (Moeckli et al., 1992). These findings 
suggest that HEV infection, unlike that of enterically transmitted agents, is not frequent 
among young children in developing countries. However, in a recent report from India anti-
HEV were detected in more than 60% of children below the age of 5 years (Aggarwal et 
al.,1997). The differences between disease-endemic may be related to varying 
epidemiological condition in different geographical areas,  differences in diagnostic 
techniques used, or both. In developed countries 1-5% of population have anti-HEV 
antibodies (Yarbough et al.,1992). This range appears to be relatively high compared  with 
the low rate of clinically evident hepatitis E disease in these areas. However, in a  recent 
study that used two different serological test to estimate the prevalence of anti-HEV, 
concordance between the two test was 27% (Favorov MO et al. 1997). Enzyme 
immunoassays currently used in various laboratories  were directed compared using a 
panel of coded samples. Seroprevalence studies indicates that HEV EIA´s based on 
large antigens expressed  from ORF2 or capsid-like particles are superior to those based 
on short sequences of ORF2 or antigenic epitopes of the ORF3 in detecting convalescent-
phase anti-HEV (Worm et al 2002). It should be noted however, that the overall 
concordance of different tests for assessing the seroprevalence of anti-HEV in a non-
diseased population is low. Pair-wise comparison of twelve test set show a concordance 
in blood donor sera raging from 41% to 94% (mean 68%), and a concordance among 
reactive sera from 0% to 89% (mean, 32%) (Mast et al, 1998). EIAs based on synthetic 
peptides could be not detected the convalescent-phase anti-HEV reliably. They are used 
mainly to confirm positive test results from EIA based on recombinant proteins and 
exclude non-specific anti-HEV in a acute-phase serum (Takashi et al, 2003). The 
specificity and sensitivity of these tests for detecting convalescence-phase IgG  have not Hepatitis E - Virus (HEV): 
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been precisely established, which limits the reliability of the results from 
seroepidemiological studies.  Our study showed that their sensitivity rates varied  widely 
(from 17-100%), and concordance rates among reactive serum specimens range from 
none to 89% (median 32%) (Purcell et al Hepatology 1998). The assays compared in this 
study used recombinant HEV proteins, which differ in length, part of the genome with 
which they correlate, and the geographical strain of HEV to which they correspond. Thus, it 
remains unclear whether the anti-HEV seroreactivity in non-endemic  areas reflects 
subclinical  and /or anicteric HEV infection, serological test , or a combination of all these 
factors. 
 Hepatitis E - Virus (HEV): 
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1.11  Therapeutic Approaches to Hepatitis E Infection 
No therapeutic compounds against hepatitis E are currently available; the  only treatments 
are supportive in nature. Possible drug targets include the HEV Pr and RdRP enzymes on 
which even the basic biochemical information is not yet available. Such information will be 
critical for developing assays to screen libraries of natural or synthetic molecules to search 
for compounds with anti-HEV activity. The HEV RNA 5´and 3´ ends appear to interact with 
viral and cellular proteins and are crucial for its replication; strategies designed to block 
these interactions, for example with anti-sense oligonucleotides, ribozymes or small 
molecules, might be of therapeutic value. No information is available as to whether any of 
these approaches are currently being employed. HEV, or ET-NANBH virus as it was 
called then, was recognised as a distinct entity in the early 1980s. It took almost 10 years 
to develop suitable animal models and obtain epidemiological information. This directly 
led to cloning of viral genome in 1990 (Reyes et al., 1990) and designation as HEV. Along 
with the molecular cloning of the HCV genome a year earlier, this heralded a new age in 
molecular virology, in which the genomes were cloned without first isolating or propagating 
the virus in culture .The initial cloning of the genome of the Burma isolate of HEV (Reyes 
et.al.,1990) led to the subsequent cloning of genomes from other geographically distinct 
isolates and  development of a diagnostic test. These developments have further 
increased our knowledge of t he epidemiology of hepatitis E. However, the pace of 
research on hepatitis E has been slow for a number of reasons. Hepatitis E is not a 
significant health problem in countries have technological capabilities and funds to carry 
out front-line biological research.  Furthermore, HEV causes an acute, self-limiting 
infection with no associated chronicity, unlike HBV and HCV. However, new findings that 
hepatitis E might have zoonotic reservoir and indigenous pockets of infection in 
industrialised nation, and the identification of risk groups of displaying high mortality such 
as pregnant women, are likely to provide impetus to hepatitis E research.  Hepatitis E - Virus (HEV): 
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This would be especially welcome in the direction of anti-HEV vaccines and therapeutics. 
Limited information available on the molecular biology of HEV shows to be interesting, 
virus that might serve as a good model to study virus- host interactions at the molecular 
level (Shahid et.al.,1999). Perhaps this will also stimulate research. Hepatitis E - Virus (HEV): 
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1.12  Immunoprophylaxis 
No products are currently available to prevent hepatitis E. Passive immunization using 
immuneglobulins prepared from plasma collected from HEV-infected persons in non-
HEV-endemic areas is not effective in preventing clinical disease during hepatitis E 
outbreaks, and the efficacy of the immuneglobulins prepared from plasma collected in 
HEV-endemic areas is also unclear (Shahid et al., 1999). 
In studies with prototype anti-HEV vaccines in animals, vaccine-induced antibody could 
attenuate HEV infection but did not prevent virus excretion in the stools of infected 
immunised animals. For viral pathogens that are difficult to culture and therefore not easily 
amenable to the development of live attenuated strains, a promising approach is to 
develop subunit vaccines. A subunit vaccine consist of a part of the virus, typically a 
protein capable of generating a protective immune response in immunised persons. 
Recombinant DNA technology is now routinely used to generate large amounts of purified 
viral proteins to be used as subunit vaccines. For HEV, the most promising subunit 
vaccine candidate so far appears to be the ORF-2-encoded protein when expressed in 
insect cells using recombinant baculoviruses. Two of such candidates were developed 
simultaneously at the National Institutes of Health(Bethesda, MD USA) at the Genlabs 
Technologies (Redwood City, CA, USA) (Zhang Y et al..1997). 
After a pilot-scale production at the Smith Kline Beecham (Belgium), both vaccine 
undergone feasibility testing in experimental animals and have shown promise (Fricker .et. 
al.1999). The NIH vaccine candidate has  also been subjected to a Phase I trial in US 
volunteers and has been shown to be safe and immunogenic. A similar trial of  this 
candidate vaccine in Nepal, an area endemic for hepatitis E has been started in last year 
(results unpublish). Immunogenicity and efficacy data should be available sometime in the 
near future and will help answer many question still remaining. One question yet 
unanswered concerns the number of epitopes on the Virion. Only neutralisation epitope 
has been thus identified thus far (Emerson et al.,2000 ; Meng et al, 2001): it maps 
between amino acids 578 and 607 0f the capsid protein (Emerson et al, 2003). Virus 
mixed in vitro with either of two monoclonal antibodies that recognised this epitope was 
unable subsequently to infect macaques. This epitope should be present in each of the Hepatitis E - Virus (HEV): 
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baculovirus-expressed candidate vaccine. However, this epitope should not be in the 
shorter protein that forms VLPs but includes only amino acids 112-578. Interestingly, 
vaccination with this shorter protein did not prevent rhesus macaques from hepatitis 
following a high dose challenge although the virus load appeared to be reduced (Emerson 
et al, 2002).  At this time, there is no good explanation as why vaccination with either the 
112-607 or 112-578 protein reduced virus shedding to a similar extent whereas only the 
larger protein afforded protection from hepatitis.(Emerson et al, 2003). Another 
unanswered question has a more practical aspect. It concerns the duration of immunity 
induced vaccination. Recently, the  products of N-terminally truncated ORF-2 were shown 
to form empty virus-like particles (VPLs) (Li TC et al 1997). These VLPs retain native virus 
epitopes and appear to be good vaccine candidate(He J. et al  !997). Alternative 
strategies for developing anti-HEV vaccines are also being tried in research laboratories. 
A naked DNA immunisation approach in which ORF-2 was injected as an expression 
plasmid directly into muscles resulted in moderate anti-ORF-2 titres in mice (He J et al 
1997;) within days of ORF-2 plasmid DNA injection, the subsequent injection of genes 
encoding either of the immunomodulatory cytokines interleukin 2(IL-2) or granulocyte-
monocyte colony-stimulating factor GM-CSF) resulted ain higher anti-pORF-2 titres in 
mice (Shahid et.al.,1999). Hepatitis E - Virus (HEV): 
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1.13  Prevention 
Any improvements in water quality and sanitation will be helpful in preventing transmission 
of HEV since most of the outbreaks described can be attributed to contaminated water 
supplies. Improvement should be wherever possible. Although passive protection has 
been demonstrated in animals (Emerson et al, 2003), when administration of 
immuneglobuline has been tried in humans it has met with disappointed results. Such 
preparations are particularly of little value if  they are produced in countries where HEV is 
not endemic and there is little immunity. Arankalle et al, 1998 and Khuroo et al, 1996 
looked at the efficacy on an Indian preparation of immune serum globulin. 
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1.14  Objective 
 To evaluate the suitability of currently available HEV IgG antibody assays for use in low-
endemicity areas. Sera referred for routine antibody screening, mostly from long-term 
expatriates ( development aid workers and family members). Samples reactive by Abbott 
HEV antibody EIA since April 1998 were included in the panel. 
Paradoxon: HEV antibody seroprevalence  rates 
1)  in endemic areas lower than expected ( compare with Hepatitis A) 
2)  but in non-endemic areas higher than expected, in the absence of a consisitence 
clinical or travel history ( e.g in blood donors). 
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2  Methods and Materials 
2.1  Methods  
 
Sera were selected on the basis of al least borderline reactivity in the routinely used Abbot 
EIA. Most were tested as part of routine screening of long-term expatriates in endemic 
countries. The following assays (recombinant anitigens) were used : Abbott  EIA, 
Genelabs ELISA, Mikrogen recomBlot and a Prototype DSL ELISA. 
 
 
HEV ANTIGENS EMPLOYED 
Abbot EIA: 
SG-3 327aa): C-terminus of ORF2 
8-5 (123aa): full ORF3 
Burma strain 
 
 
GENELABS ELISA: 
Type-common epitopes of ORF2 and ORF3 
Mexico and Burma strains 
 
MIKROGEN RECOMBLOT 
N-terminal, C-terminal, middle portion of ORF2, full ORF3 
Madras isolate 
 
DIAGNOSTIC SYSTEMS LABORATRIES ELISA 
ORF2 
ORF3 
Burma strain Hepatitis E - Virus (HEV): 
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2.2  Materials 
ABBOTT  EIA 
Biological Principle of the procedure. 
In the Abbott HEV EIA, human serum or plasma is diluted in a spicemen diluent and 
incubated with a  polystrene bead coated with recombinant HEV proteins representing 
sequences from Open Reading Frame (ORF2) and ORF3 of the Burmese strain of HEV. If 
antibody is present in the sample, immunoglobulins in patient sample are fixed to the 
coated bead. After removing the unbound materials and washing of the bead, human 
immunoglobins remaining bound to the solid phase are detected by incubating the bead-
antigen-antibody complex with a solution  containing horseradish peroxidase labeled goat 
antibodies directed against human immunoglobulins 
Unbound enzyme conjugate is then removed and the beads are washed. Next, o -
Phenylendiamine (OPD) solution containing hydrogen peroxide is added to the bead and, 
after incubation, a yellow-orange colour develops in proportion to the amount  of anti-HEV 
which bound to the bead. 
 Specimens with absorbance values less than   the  Cut-off Value are considered initially 
reactive by the ABBOT HEV EIA and then repeated in duplicate .Specimens with 
absorbance values within ± 10% of the Cut-off Value are considered to be in the grey zone 
and should be retested in duplicate to confirm the initial results. 
2.3  Test Principles: 
2.3.1 Diagnostics Systems Laboratries ELISA 
Hepatitis E kit is based on the ELISA technique (Enzyme linked Immunosorbent Assay). In 
the assay, Negative, Positive Controls and unknowns are incubated in microtitration wells 
coated with recombinant derived HEV antigen of ORF2 and ORF3. After incubation and 
washing, the wells are treated with the conjugate, composed of anti-human IgG-
monoclonal antibodies labelled with peroxidase. After a second incubation and washing 
step, the wells are incubated with the substrate tetramethylbenzidine (TMB). An acidic Hepatitis E - Virus (HEV): 
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stopping solution is then added and the degree of enzymatic turnover of the substrate is 
determined by wavelength absorbance measurement at 450 nm. The absorbance 
measured is directly proportional to concentration to the anti-HEV antibodies present. 
ASSAY PROCEDURE 
All specimens are reagents must be allowed to reach room temperature (25°C) before 
use. Serum Samples, Control Positive and  Control Negative should be assayed in 
duplicate. 
Mark the microtitration strips to be used. Dilute the serum samples 1:101 distributing 10 µl 
of serum into 1 ml of Assay Buffer. Pipette 100 µl of each of each diluted serum sample 
ready to use positive control, negative control serum to the appropriate wells. Leave one 
for the blank, and performed using 100 µl of the  substrate mixture. Cover the wells with 
protective film and  incubate for  45 minutes at 37 °C. Aspirate and wash each well four 
times for 30 seconds with Washing Solution using an automatic microplate washer or 
manually using dispenser (e.g. Multipette Ependorf).  
Blot and dry by inverting plate on absorbent material. Add 100 µl of Enzyme Labelled 2
nd. 
Antibodies into each well. And cover the wells with protective film and incubate for 45 
minutes at 7°C. Aspirate and wash each well four times for 30 seconds with Washing 
Solution using an automatic microplate or wash manually using dispenser (e.g. Multipette 
Eppendorf). Blot and dry by inverting plate on the absorbent material. Add 100 µl  of TMB 
Chromogen . 
Solution to each well using a dispenser And then incubate for 10 minutes at room 
temperature and avoid exposure  to direct sunlight. Add 100 µl of Stopping Solution to 
each well using a dispenser. Read the absorbance of the solution in the wells within 30 
minutes, using a microplates reader set to 450nm. If wavelength correction is available, 
set the instrument to dual wavelength measurement at 450 nm with background 
wavelength correction set at 600 or 620 nm. Hepatitis E - Virus (HEV): 
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2.4  Genelabs ELISA 
 
2.4.1 Chemical and Biological Principles of the Procedure 
The wells of the polystrene microplate strips are coated with three recombinant HEV 
antigens which correspond to the structural regions of the Hepatitis E Virus. Humans 
serum or plasma, diluted in diluent buffer, are incubated in these coated wells. HEV 
specific antibodies , if present, will bind to the solid phase HEV antigens. The wells are 
thoroughly washed to remove unbound materials and a mouse  monoclonal anti-human 
IgM labelled with horseradish peroxidase is added to the wells . this labelled antibody will 
bind to any antigen-antibody complexes previously formed and excess unbound labelled 
antibodies are removed by washing a substrate solution containing hydrogen peroxide 
and o-Phenylenediamine Dihydrochloride (OPD.2HCL) is then added to each well.  
The presence of specific antibodies is indicated bye the presence of a yellow-orange 
colour after substrate addition. Reaction is terminated bye addition of sulpheric acid. The 
intensity of the colour measured spectrophotometrically at 492nm and is proportional to 
the amount of antibodies present in the specimen. 
2.4.2 Assay Procedure 
Remove microplate from the aluminium bag and shake specimen and control 
vials before use.. Then fill a reagent reservoir with Diluent. .By using a multi- channel  
pipettor, add 200ul of Diluent to all wells. Wells A1 and B1 are ´BLANKS´. Add an 
additional 10ul of diluent to these wells. 
Then add 10ul of specimen to the assigned well, starting at  well H1. This will give a final 
specimen dilution of 1:21. Add 10ul of Non-reactive Control to wells C1, D1 and E1.Add 
10ul to wells F1 andG1 and mix thoroughly by tapping gently on all sides of microplate, 
taking care to keep the plate flat on the bench-top. Carefully cover microplate with a plate 
cover provided to prevent evaporation during incubation. Incubate for 30 minutes at 
37°C.Prepare Working Conjugate as describe in the Preparation of Reagents prior to 
washing to washing the microplates. Then wash the microplate with dilutet buffer. Blot dry Hepatitis E - Virus (HEV): 
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by inverting the  microplate and tapping firmly onto  absorbent paper. Add all residual 
plate wash buffer should  be blotted dry. Colour formation can be inhibited  during  the 
substrate  incubation by residual plate buffer. Fill a reagent reservoir with the Working 
Conjugate using a multi channel pippetor , add 100ul of Working Conjugate to all wells and 
apply another cover. Incubate the microplate for 30 minutes at 37°C. Prepare Working 
Substrate Solution as according to instructions  in the Preparation of Reagents. Shield the 
substrate from light. 
 Excess solution should be  discarded after use. After that, remove and discard the plate 
cover. Fill reagent  reservoir with Working Substrate Solution. Using a multi channel 
pippettor, add ^00ul of  Working Substrate Solution to each well.  Incubate for 15 minutes 
in the dark at room temperature.  Then using a multi channel pipettor, add 50ul of Stop 
Solution to each well. and mix gently by tapping the plate. 
Determine and Absorbance  for each well at 294 nm . If a dual filter instrument is used, the 
reference wavelength should be 620 nm. 
2.5  Mikrogen Recomblot 
TEST PRINCIPLE: 
The purified, recombinant antigens used are separated according to their molecular 
weight by using SDS polyacrylamide gel eletrophoresis. The HEV proteins are then 
transferred electrophoretically  to a nitrocellulose membrane (Western Blotting). The 
membrane is subsequently incubated with a protein solution to block free binding sites, 
washed, cut into strips, and then into tubes. 
To detect, HEV-specific antibodies, the strips are incubated with the diluted  serum 
sample. During incubation, the antibodies bind to the antigens fixed on the  strips are 
incubated (2
nd)  with anti- human-IgG or anti-human-IgM coupled to horseradisch. 
Specifically bound antibodies are detected by a peroxidase- catalyzed colour reaction. 
Dark bands appear on the test strip, showing the presence of reactivity against one of the 
HEV proteins. As the reaction control, a band of anti-human immunoglobulin, which must 
show a reaction with every serum, is applied at the top end of the strip below the number. Hepatitis E - Virus (HEV): 
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2.5.1 Test Procedure 
2.5.2 General Aspects. 
The reproducibility of Western blot results depends to a great extent on the uniform 
washing of the strips. Therefore, the washing frequencies described. 
First Incubation: 
Before use, all reagents must be brought to room temperature (18-25°C) for about 30 
minutes. The test is also carried out at room temperature. Spin reagents and control sera 
in the small reaction tubes prior to use.. One well in an incubation tray is required for each 
test. 2 ml of ready-to-use wash/dilution buffer are pipetted into each wells. With the help of 
plastic tweezers, one test strip is carefully dipped into each of the wells. filled with wash 
buffer. The number of the strip should point upwards. 
Addition of Sample: 
IgG test procedure: in each incubation batch 33 µl of an undiluted sample (human serum 
or plasma) or  the corresponding weak positive control are pipetted into the designated 
well (1:60). 
IgM test procedure: in each incubation batch 33 µl of an undiluted sample (human serum 
or plasma) are pipetted  into the designated well (dilution 1:60). (weak positive control not 
available) 
In each experimental run, the corresponding weak positive control should be included, 
irrespective of the  number of sera to be tested. 
The incubation tray is covered with the plastic lid and incubated with gentle 
shaking for 2 hours at room temperature. The incubation temperature should be between 
18 and 25°C. It is very important that no contamination occurs between neighbouring 
wells, possible giving an in correct positive results. Hepatitis E - Virus (HEV): 
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Washing: 
After incubation, the plastic lids are carefully removed from the incubation trays. The 
diluted serum is carefully withdrawn from each well, preferably with a withdrawal device 
that has an attached desinfection trap.2 ml of ready-to-use wash buffer are subsequently 
added to each well and incubated on the shaker with gentle shaking for 5 minutes. The 
wash buffer is withdrawn after incubation. The washing steps is repeated  altogether four 
times. 
Second Incubation: 
After washing the strips, 2 ml of the correspondingly prepared conjugate are added to 
each well and incubated with gentle shaking for one hour at room temperature. The 
incubation tray should be covered during  this process. The conjugate solution are 
withdrawn from wells and the strips are washed and again. 
Third Incubation: 
2 ml of ready-to -use substrate solution are added to each wells and incubated with gentle 
shaking for 10-15 minutes  at the room temperature. 
Stop the reaction: 
After withdrawal of the substrate solution, the strips are washed three times with deionised 
water. Using tweezers, the strips are carefully taken out of the water and between 
absorbent paper for 2 hours to dry. Subsequently, the strips can be stuck onto the 
attached evaluation sheet and the result recorded. Hepatitis E - Virus (HEV): 
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2.6  Assay Procedure 
Dilution of specimen 
A dispense of 10ul of each control or specimen into the bottom of an individual test tube, 
and a dispense of 200ul of specimen diluent to each test tube. containing sample. and 
then ensure adequate mixing by a gently tapping..10ul of each diluted control or specimen 
will be transferred into appropriate well of reaction tray. Add  a dispense 200ul of 
specimen diluent  to appropriate tray containing  control or specimen and after that a 
adequate mixture. by tapping. Hepatitis E - Virus (HEV): 
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First Incubation: 
Carefully add one bead to each well containing diluted  control or specimen and apply 
cover seal. After that, gently tap the tray to cover beads and remove  any trapped  air 
bubbles. Then incubate at 40°C for 65minutes in a Water Bath.. After that, remove and 
discard  the cover seal. Aspirate the liquid and wash each  bead three times for a total 
rinse volume of 12 to 18 ml of distilled or deionised water. 
Second Incubation: 
Pipette 200ul of diluted conjugate into each well containing a beads. Apply new cover seal 
and gently tap the tray to cover the beads and remove  any trapped air bubbles. Then 
incubate it at 40°C for 65 minutes in a Water Bath. 
Remove and discard c over seal and aspirate the liquid and wash each bead as first 
incubation. 
Colour Development 
Then immediate transfer of the beads to properly identified assay tube. Pipette 300ul of 
freshly prepared OPD substrate solution into two empty tubes (substrate blanks) and then 
into each tube containing a bead. Cover and  
incubate at room temperature for 30 minutes and add 1ml of 1N Sulfuric Acid in each 
tube. 
Reading: 
Blank spectrophotometry with a substrate blank at 429nm. Determine absorbance of 
controls and specimens at 492nm within two hours after addition of acid. Hepatitis E - Virus (HEV): 
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2.7  Test Interpretation 
 
ABBOTT EIA: 
Cut-off = mean NC + (0.45* mean PC) 
Grey zone = cut-off +- 10% 
If sample O.D. > cut-off……. Repeat in duplicate 
 
GENELABS ELISA: 
Cut-off = mean NC + 0.5 
Grey zone not define 
If  sample O.D. > cut-off……. Repeat in duplicate 
 
DIAGNOSTIC SYSTEM LABORATRIES ELISA: 
Cut-off = mean NC +0.1 
Sample O.D.> cut-off……. Positive 
Sample O.D.< cut-off  but > cut-off  -10%…… borderline 
Sample O.D. < cut-off  - 10%…….negative 
 
MIKROGEN RECOMBLOT: 
reaction control 
 
O 2 - N 
 
O 2 - C 
 
O 2 - M 
 
 
O 3 Hepatitis E - Virus (HEV): 
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´´Scoring´´ system: 
uppermost band of triple band O2-C with weak- positive control serum : +; 
 
  no band visible  -  0 point 
  very weak band  +-  1 point 
  weak band  +  2 points 
  strong band  ++  3 points 
      maximum score :    12 points 
 
 
Interpretation :  
 
4-12 points : positive 
3 points       ´´questionable´´ 
0-2 points     negative 
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RESULTS. 
Table 1: Results Sample I 
 
Assay  positive  borderline  negative  total 
Abbott  59  22  0*  81 
Genelabs  22  0  45  67 
Mikrogen  36  5  8  49 
dsl  43  4  14  61 
 
 
Table 2: Samples tested by all 4 assays 
 
Assay  positive  Borderline  negative  total 
Abbott  32  12  0*  44 
Genelabs  20  0**  24  44 
Mikrogen  31  5  8  44 
dsl  33  2  9  44 
 
* selection criterion    ** not defined 
 
 
Our experience in Frankfurt am Main  
over the past four years (starting 1 Jan 1998) 
 
 
  all  male  female   unkn  % positive 
total tested  1184  716  423  45  100 
positive  57  28  29  0  4.8 
borderline  40  25  13  2  3.4 
negative  1087  663  381  43  91.8 
 
 
 
•Concordance between assays  (pairwise;  
    categories: positive, borderline, negative) 
: 
 
￿  Abbott  versus  Genelabs:    36.4 % 
￿  Abbott  versus  Mikrogen:    56.8 % 
￿  Abbott  versus  dsl:      54.6 % 
￿  Genelabs  versus  Mikrogen:  61.4 % 
 
 
•Disagreement between assays (pairwise;  
    categories: positive/negative or vice versa): Hepatitis E - Virus (HEV): 
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￿  Abbott  versus  Genelabs:    50.0 % 
￿  Abbott  versus  Mikrogen:    9.1 % 
￿  Abbott  versus  dsl:      13.6 % 
￿  Genelabs  versus  Mikrogen:  27.3 % 
 
  
 
 
 
Figure : 6  Frequency distribution: Genelabs EIA
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Frequency distribution: Mikrogen Western blot.  
Figure:7 
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3  Results and Discussions 
3.1  Abbott EIA Assay 
.    Eighty-one patients who had  been determined to be positive for HEV RNA were selected 
in this study. The serum samples  were stored at –80°C until tested  for anti-HEV IgM and 
anti-HEV IgG u sing an enzyme immunoassay (Abbot GmbH Diagnostics, Wiesbaden 
Germany) This assay is based on two recombinant antigens (ORF2 and ORF3) derived from 
different open reading frame of the Burmese of HEV expressed as a CMP-2-keto-3-
deoxyoctulosonic acid synthetase fusion protein in Escherischia-coli .These samples were 
tested  in accordance with the manufacturer´s instructions, and those  with absorbance less 
than the Cut-off (CO) value were considered negative. Samples with the absorbance(S) 
greater than or equal to the CO value were tentatively considered reactive and then retested  
in duplicate to confirm the result. Results were recorded as S/CO ratios to allow comparison 
of the intensity reactions of individual samples. The samples were considered reactive when 
S/CO was higher than 1.0. 
Fifty-nine turned to be positive and twenty-two reactive. This study confirms the high 
prevalence of anti-HEV in countries where clinical hepatitis E is not endemic. The reason for 
this study could  reflect a mixed source of infection. A proportion of human HEV infections 
probably occur through exposure in the endemic regions since  some of  these  patients  were 
workers in these regions. But secondary spread of HEV infections between humans is not 
common (2% secondary cases compared to 15% for HAV) (Skidmore et al 1995), and the 
majority of the study population had no travel exposure , so this could explain a minority of 
cases (Christensen et al., 2002). We had access to serial specimen collected over months 
from 81 hepatitis E patients. This specimens demonstrated that IgM antibody levels were  
very high soon after illness onset, declined little over several weeks, and then declined rapidly 
to low levels over next 4 to 6 months. This is typical of IgM responses to other acute, self-
limited, systemic viral infections (Seriwatana et al.,2002). 
The weeks-long duration of markedly elevated IgM levels after disease onset means that the 
diagnosis using relatively sensitive IgM detections methods should be successful,  even if 
patients come to medical attention late. We began  this study anticipating that an HEV IgM Hepatitis E - Virus (HEV): 
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test would improve serological diagnosis on hepatitis E, then based on detection of HEV-
specific IgG. We confirmed that the detection of HEV IgM is the best  serological test for 
diagnosis of hepatitis E. Yet the most interesting  aspect of our work was the observation that 
in some cases of hepatitis E, there was a weak or absent IgM response. By combining HEV 
IgM and IgG test, we identified primary immune responses among the hepatitis E patients in 
areas of HEV IgM to- total IgG ratio. 
This is an important observation because previously, some authorities have speculated that 
waning immunity explained why most cases of hepatitis E among adults. The fact that more 
than 90% of hepatitis E cases in areas of HEV endemicity  occur in patients who have a 
primary response refutes this speculation of waning immunity, since previously exposed 
persons should mount an anamnestic response upon reexposure (Seriwatana et al 2002). 
3.2  Genelabs ELISA 
 Detection of antibodies in sera of patients with Hepatitis E by use of Genelab assay. 
Sixty-seven patients with clinical symptoms of acute hepatitis were diagnosed as having 
hepatitis E on the basis of detection of antibodies by the Genelabs assay. These 67 samples 
were tested by EIA based on the recombinant polypeptides from HEV genotypes 
encoded by ORF2 and ORF3 of HEV genome (Genelabs Diagnostics, Singapore). The 
assay was performed according to the instruction of the manufacturer. The results showed 
that twenty-two of this samples were positive and forty-five were negative. These tests were 
conducted at least three times. HEV antibodies were determined by ELISA of distinct 
antigenic specificity. In this study we observed   a wide range of sensitivity and specificity. 
This information implies that  this assay might be unreliable for the diagnosis of HEV infection 
in areas where hepatitis is not endemic. However, most anti-HEV assays  have not been 
correlated with the HEV RNA determined by reverse transcription (Lin et al., 2000).  In this 
study, we evaluated  the diagnostic value for acute hepatitis E patients and in long-term 
expatriates of commercial anti-HEV IgG and IgM enzyme linked immunosorbent assays 
(ELISA) relative to RNA detection. The prevalence of anti-HEV among the general population 
in Frankfurt was also re-evaluated with this assay. We found a fairly good sensitivity (70%) of 
the IgG anti-HEV for the diagnosis acute hepatitis E verified by HEV RNA. However, the Hepatitis E - Virus (HEV): 
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sensitivity (50%) of the IgM anti-HEV appeared to be less satisfactory. In previous reports, 
anti-HEV detection had a wide range of sensitivity and poor concordance among different 
assays (Mast et a.,1998). 
The sensitivity of IgG anti-HEV in this study was comparable to that of previous reports 
(Favorov et al.,.1998) and (Meng et al ., 1999 ). 
However, the sensitivity of IgM was relatively poor. Our study might underestimate the 
sensitivity of these assays, since about five of the IgG anti-HEV-negative serum samples has 
tested positive for IgG anti-HEV with the same kit in a previous test. These discrepant results 
might be due to low-titer  antibodies having been destroyed by repeated freezing and thawing 
in the later test. There are three possibilities for low sensitivity  of IgM anti-HEV in this study. 
The first, delayed sampling, might account for negative IgM  anti-HEV in some patients. 
Although both HEV viremia  and serum IgM anti-HEV were short-live (Koshy et al.. 1996 ), 
protracted viremia has been reported for as long as one to four months in some  patients 
(Nanda et al.,1995) IgM anti-HEV might have declined to an undetectable level before 
disappearance of HEV RNA. The second possible explanation is sequence variations among 
different HEV genotypes. It was reported that IgM anti-HEV were detectable in a patient with 
HEV strain US-1 using an assay based on Burmese and Mexican strain (Ferguson et al., 
2002). It is likely that IgM anti-HEV have been undetectable in some of patients infected with a 
same genotype  HEV using the same assay based on different genotypes (Tian-Chang et 
al.,2000). Finally, a poor host immune response to HEV infection might also account for 
undetectable IgM anti-HEV in some of our patients, as a evidenced by lower IgG anti-HEV 
optical density values in acute hepatitis E patients who were negative for IgM anti-HEV. We 
observed that, antibodies status may differ with the stage of disease, and screening of a 
population with a significant number of individuals in a convalescent phase could give results 
from those present study in terms of immunoreactivity to each of the three recombinant 
polypetides (Younchun, W et al.,.2001). The results of our study suggest that some patients 
diagnose provisionally as having non-A to non B–Hepatitis in Frankfurt may in fact, have 
hepatitis E and a single test for anti-HEV IgG is insufficient for diagnosis. The relatively low 
positive rate of circulating antibodies (observed in out test IgG anti-HEV) in the populations of 
the endemic areas combined with the unexpectedly high prevalence of anti-HEV in non-
endemic countries like Germany make the interpretation difficult. Because of lack of antibody Hepatitis E - Virus (HEV): 
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detection assays the significance of HEV infection, that is without doubt a serious infection in 
developing countries, might be underestimated in developed countries (Schlauder et al 
1999). 
In conclusion, the overall sensitivity and specificity of the Genlabs ELISA seemed to be the 
same as those shown in previous publications (Li et al, 1998) and (Mast et al, 1998), probably 
because both the present and the previous assays used the baculovirus –expressed capsid  
proteins. The serological tests with sera collected from hepatitis E patients indicated a that 
the circulating IgG antibody was maintained at a high level.  
3.3  Mikrogen RecomBlot:  
Detection of anti-HEV IgG in sera from patients with hepatitis E. 
To  select conditions for a sensitive diagnostic assay and to examine the dynamics of 
antibody responses to each fusion proteins, Western blots were conducted to detect anti-
HEV IgG from sera from patients with  hepatitis E. Out of  forty-nine sera selected, thirty-six 
were positive, five were reactive and eight negative. Each sample was tested at least three 
times in single wells. Any sample which was positive on the either initial test was retested in 
duplicate. Samples in which both duplicate wells were positive were designated as a 
confirmed positive, all other were considered negative. A Western  blot assay was developed  
for detection of anti-HEV with three HEV-GST fusion proteins. GST-ORF2.1 and GST-
ORF2.2, which encoded by portions of ORF2 
Overlapping at the entire ORF3 from a Chinese strain of HEV. This assay proved to be 
sensitive and specific for HEV in tests with sera from patients with different types of acute 
hepatitis, and to our knowledge it is the first assay described which detects long –lasting  
antibody reactivity in a high proportion of patients and experimentally infected animals (Zhang 
et al.,2002). The detection of this persistent antibody reactivity represents an important 
advance in the understanding of immunity to HEV infection.  
Many serum specimen used in this study were previously tested for anti-HEV IgG with 
commercial Abbot tEIA and Genelabs ELISA. This Western blot therefore, shows utility as a 
diagnostic assay for HEV infection. While IgM and IgG –class antibodies were detected in 
this study, previous publications show a high specific IgM reactivity against the fusion proteins Hepatitis E - Virus (HEV): 
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in acute-phase hepatitis E sera. However, we observed that the reactivity is not consistent. 
The molecular cloning of HEV genome (Li et al, 1994 and Jameel et al 1999) and the 
expression of recombinant proteins have allowed the development of numerous diagnostic 
and research immunoassays. However, problems remain both with specificity of some 
assays particularly when applied to seroepidemiological  study as observed in our study 
(Thomas et al 1997; Mast et al 1998). One major problem in the seroepidemiological studies 
of HEV infection  is the variable reactivity of recombinant antigens with respect to detection of 
past infection (Mast et al 1998; Scholfield et al 2000). Many HEV antigens, including synthetic 
peptides, recombinant antigens based on ORF3, and most fragment of ORF2 when 
expressed in Escherichia-coli, have reactivity with acute phase sera but little or variable 
reactivity with convalescent sera (Mast et al 1998). For example, the ORF2 antigen 3-2(M) 
was reactive with IgG from 91% of HEV-infected patients from Egypt at the time of admission 
, but fell to between 27 and 50% at 6-12 months after admission., while analogous 3-2(M) 
antigen was unreactive with only 64% of the sera at admission and none after (Goldsmith et al 
1992) Conversely, the 3-2(M) was unreactive  with convalescent sera from patient infected in 
Pakistan, while the 3-2(B) antigen reactive with sera collected from patients 4.5 years after 
illness (Dawson el al, 1992). Thus while many patients become unreactive, other patients 
maintain high levels of antibody to these proteins, which makes the interpretation of reactivity 
difficult as shown in this study. This may also be true of the ´mosaic´antigens  (Favorov et al , 
1996) expressed in E. coli as represents the fusion of a number of linear peptide epitopes. 
As consequence of the variable , but generally low rate or reactivity with convalescent sera, 
these antigens have had some use for the diagnosis of acute infection in non-endemic areas 
by the detection of HEV-specific IgG , but prevalence of past infection in endemic areas must 
be underestimated . 
Conversely, a second group of recombinant antigens appear to demonstrate consistent 
reactivity with both acute and convalescent phase sera. These antigens include  HEV virus-
like or subviral particles (SVP´s) formed by truncated ORF2 expressed in insect cells using 
the baculovirus system (Tsarevet al, 1993; Li et al, 1999) and ORF2.1 expressed in E.coli. 
Such antigens are logically the most suitable for seroepidemiological studies, although the 
titre of anti-HEV may decline rapidly following the acute  phase, it appears to remain at 
detectable levels for many years (Favorov et al, 1996).  Hepatitis E - Virus (HEV): 
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The observations that the presence of such antibody correlates with protection from infection 
during epidemics (Bryan et al,1994) and that passive immunisation is sufficient to confer 
immunity to HEV disease in macaques (Tsarev et al, 1994) underline the practical value of 
detection this log-lasting antibody to HEV. Ghabral et al,1998 have recently compared assay 
for HEV-specific IgG and IgM using recombinant antigens from either baculovirus-expressed 
SVP´s or E. coli expressed fragments of ORF3 and ORF2. Their findings demonstrate the 
improved sensitivity of the SVP´s  ELISA for detection of past HEV infection, but the detection 
of very high rates of reactivity in presumed  non-endemic populations in the USA using this 
assay (Thomas et al,1997) raise the questions regarding the specificity of the assay for IgG-
anti HEV. The results of this study also have implications for the development for the 
development of more convenient assays for HEV antibody by other methods. First, the 
reactivity of the HEV fusion proteins in Western blot appears to be greater than that of native, 
synthetic proteins in an Abbott-EIA (Dawson et al., 1994). 
3.4  Diagnostics Systems Laboratories ( DSL) ELISA 
Acute hepatitis E has been rarely been reported in industrialized countries, but the rate of  
seroprevalence of hepatitis E virus (HEV) is inappriopriately high. The sensitivity and the 
specificity of the assay used to test for immunoglubulin G (IgG) and IgM anti-HEV have not 
been well established in areas where hepatitis is not endemic ( hereafter referred to as ´non-
endemic areas´). Enzyme immunoassay based on recombinant proteins of HEV have been 
used for most prevalence studies. The recombinant proteins contain immunodominant 
epitoped encoded by open reading frame (ORF2) and (ORF3) of the HEV genome from 
Burmese strain. A wide range of sensitivity and specificity has been reported for this assay 
(Bhaduree et al 1998). This information implies that this assay might be unreliable for the 
diagnosis of HEV infection in areas where hepatitis E is not endemic especially Germany. 
We collected serum samples from sixty one HEV patients and to test for IgG anti-HEV by 
enzyme-linked immunoabsorbent assay (ELISA). Forty three were positive for IgG anti-HEV, 
fourteen were negative for anti-HEV and four borderline for IgG anti-HEV. IgG class were 
measured according to the Diagnostic Systems Laboratories (DSL) procedure.  Hepatitis E - Virus (HEV): 
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3.5  Concordance Between Assays 
3.5.1 Evaluation Of Abbott EIA Versus Genelabs ELISA 
The results of serologic tests for hepatitis E have varied widely from laboratory to laboratory, 
making interpretation of seroepidemiologic studies difficult. This study compares serologic 
results with different antigens and tests developed by two laboratories (Abbott EIA and 
Genelabs ELISA) for their ability to diagnose hepatitis E and measure antibody prevalence in 
area where hepatitis E is not endemic. The concordance between both assays in specificity 
and sensitivity were 34,4% but 50 % disagreement.  Our results does not differ from other 
reported publications (Purcell et al., 1998), (Aggrawal et al, 2000), (Seriwatana et al, 2002). 
The performance of tests for antibody to the hepatitis E  virus  anti-HEV is an important factor 
in accessing the epidemiology of hepatitis E infection. Although these assays are specific, 
they have limited sensitivity: anti-HEV has been detected in only 50% to 70% of patients with 
acute hepatitis during hepatitis E outbreaks, and anti-HEV titres decline to subdetectable 
levels within several months after acute detection. Several recombinant protein-based tests 
have demonstrated increase sensitivity compared to prior assays, detecting anti-HEV in 90% 
to 95% of patients with acute hepatitis during outbreaks of hepatitis E in HEV endemic areas 
(Mast et al, 1997). 
Recently, a number of cases of hepatitis E, diagnosed on the basis of serologic testing, have 
been reported among persons who had no history of travel to endemic areas. (Christensen et 
al, 2002). 
 However, the interpretation of these findings is problematic because  few data are available 
to evaluate the performance  of anti-HEV assays for diagnosis of acute hepatitis E in this 
setting. In addition, the performance of these assays in detecting anti-HEV in persons with 
remote infection is unknown, and several studies have reported unexplained positive anti-
HEV results among persons who do not have disease or unknown exposure to HEV (Thomas 
et al., 1997).  We present the findings of a serum panel evaluation conducted to access the 
sensitivity and specificity of available tests for anti-HEV and to assess the variability in 
detecting anti-HEV among tests. The results of this study indicate that several of the 
recombinant protein assays have an adequate combination of sensitivity and specificity to 
perform well for this purpose. The peptide-based assays were generally much less sensitive Hepatitis E - Virus (HEV): 
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compared  to the recombinant protein assays and are therefore likely to be non reactive in a 
high proportion of acute hepatitis E cases. Further comparative studies that includes testing 
for immunoglobulin M IgM  –anti HEV would be useful to validate the performance of the 
recombinant protein assays for  the diagnosis of hepatitis E. In addition, the performance of 
these assays for diagnosis of acute hepatitis E in persons who do not have a history of travel 
to HEV-endemic regions need to be determined.. In prior studies, HEV isolates from various 
geographic regions have been demonstrated to have at least one major cross-reactive 
epitope by a variety of serologic assays.(Favarov et al, 1994 ;Bradley et al 1998, Krawczynski 
et al, 2000). 
  However, substantial variation in detection of anti-HEV by these tests in acute and 
convalescent-phase has been found in sera from chimpanzees infected with HEV isolates 
from various geographic regions. One possible reason for this findings is differences in the 
geographic strain-specific antigenic domains in these tests (Scholfield et al, 2000). However,  
there is little variation in the RNA sequence of ORF2 among HEV isolate from various 
geographic regions. Moreover, some assays (Scholfield et al, 2000), did not detect the anti-
HEV in chimpanzee sera even though these tests included ORF3 epitopes from the same 
geographic region as the chimpanzee inoculum. The seroreactivity of recombinant proteins 
may also vary if they are produced in different expression system or used in different tests 
formats (i.e.,Abbott EIA vrs Genelabs ELISA). In addition, all these assays were designed to 
detect human antibody, and the differences may exist in the ability of assay conjugate to 
detect chimpanzee antibody. However, if the assay conjugate were the  reason for a test´s not 
detecting anti-HEV, the assay would be expected either to be non reactive in all the 
chimpanzee sera or to have a uniform decline in seroreactivity in chimpanzee sera compare 
with human sera. 
Furthermore, seroprevalence studies among blood donors in some non-endemic countries 
have found an anti-HEV prevalence of 1% to 20%, which is relatively high compared to the 
low rate of clinically evident disease associated with HEV in these areas. (Paul et al, 1994 
,Yarbough et al, 1997). In one study, anti-HEV seroreactivity among persons living in non-
endemic regions  with increasing age and was associated with a travel to endemic regions 
findings that are consistent with prior HEV infection  (Yarbough et al., 1997). Thus, the 
interpretation of seroreactivity among patients living in non-endemic regions  is currently Hepatitis E - Virus (HEV): 
Comparative evaluation of IgG antibody assays in a low-endemicity setting 
 
  Page 64 
problematic. We therefore suggest that, further studies need to  determine highly discrepant 
results among blood donor sera. Studies are also needed to determine the significance of 
anti-HEV seroreactivity among  persons living in non-endemic HEV areas, including the 
relation of seroreactivity to exposure to the recently discovered virus in pigs that is closely 
related to human HEV isolates (Purcell et al, 1997). Finally, improved tests are needed for 
use in seroprevalence studies in nonendemic regions and confirmation tests are needed to 
very the specificity of these assays as shown in our study.  
3.5.2 Evaluation of Abbot  EIA Versus Mikrogen RecomBlot 
Despite advances in knowledge of the molecular of  biology of HEV over the past decade, the 
diagnosis and seroepidemiological study of  HEV infection have remained problematic. 
Although a large number of serological assays have been developed for HEV, (Mast el al, 
1998), have demonstrated that  there is a significant lack of concordance between many 
assays, with major problems of many assays failing to detect anti-HEV in a convalescent sera 
and/or against  heterologous HEV strains. This was a particular problem with assays based 
on synthetic peptides and many recombinant proteins expressed in E. coli, however, assay 
based on  SVP´s expressed in the baculovirus system (Mast et al 1998), and Western 
immunoblots based on the ORF2 protein Anderson et al, 1999), appear to have a satisfactory 
sensitivity for analysing convalescent sera and divergent strains. In our study, we found a 
concordance of 56% between Abbot EIA and Mikrogen Western blot and a disconcordance 
of only 9,1%. We have observed a high rate of divergent results in using both assays. The 
results show clearly an ELISA based on ORF2 fragment offers sensitive and specific of HEV-
specific IgG in both acute and convalescent sera for divergent strains of human HEV. It is 
considered that the utility of this antigen is due to the efficient presentation of a highly 
conserved, confirmational epitope which is immunodominant in convalescent antibody 
response.(Anderson et al, 1999). It was observed recently that ORF2 also has optimal 
reactivity with convalescent sera from domestic pigs naturally infected with a swine HEV in 
Australia (Chandler et al, 1999). Taken together, the results suggest  that the use of 
conserved epitopes  such as ORF2 for detection of anti-HEV may be more effective than the 
use of multiple, strains-specific epitopes which is by definition dependent on identifying all 
possible strains of the virus .However, further studies will be required to establish the reactivity Hepatitis E - Virus (HEV): 
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of ORF2 with numerous distinct HEV genotypes which have recently been described. (Hsieh 
et al, 1998; Erker et al, 1999; Schlauder et al, 1999; Wang et al, 1999). 
 It has been shown in previous studies, that using SVP ELISAs   levels of HEV-specific IgG fall 
by approximately 90% following the acute phase infection, but then remain stable (Tsarev et 
al, 1993; Bryan et al, 1994) This antibody is also thought to correlate with immunity to 
reinfection (Bryan et al, 1994), and it is therefore appropriate to measure the levels of specific 
anti-HEV rather than only the presence antibody. The above listed HEV epitope may one of 
reasons high divergent of these assays used in our study. In this regard, the quantitative 
characteristics of  the IgG ELISA  reported should prove very useful, and the availability of the 
international Reference HEV serum reported by Fergusson et al, 2002  should further assist in 
studies of HEV immunity. Previous reports of both Abbot EIA and Western blot assays for 
anti-HEV have described similar rates of detection for acute hepatitis E (Mast et al, 1998) 
however, the detection of past infection appears to be less efficient, with rapid decline in 
antibody reactivity within weeks and months. 
  It is believed that the IgG ELISA based on ORF2 antigen offers a reliable method for the 
detection and quantitation of antibodies against HEV. The results of this study also have 
implications for the more convenient assays for HEV antibody by other methods .The use of 
both assays should assist in greater understanding of HEV immunity and the epidemiology of 
HEV world wide. 
3.5.3 Evaluation of Genelabs ELISA Versus Mikrogen RecomBlot 
The ELISA reported here detects both anti-HEV-IgM and anti-HEV-IgG and it is a convenient 
method for the diagnosis of acute or past HEV infection. To characterize the relationship 
between antibody potency determined  by a widely used commercial test kits. In this study, we 
compared the sensitivity and specificity of  both assays Genelabs EIA and Mikrogen Western 
blot. We observed a concordance of about 61,4% and a high disagreement of about 27,3% 
between the assays. The commercial test employ a mixture of a recombinant HEV ORF2 and 
ORF3 polypeptides expressed in E. coli. The disagreement in our study have raised the 
question about the sensitivity and specificity of these current available test for ant-HEV as well 
as questions about how long anti-HEV can be detected after infection of HEV. The variable of 
persistence of IgM anti –HEV and IgG anti-HEV makes it difficult to accurately determine the Hepatitis E - Virus (HEV): 
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frequency of prior exposure and raises the possibility of re-infection after disappearance of 
this antibody (Zhang et al.,2002).This might allude to a high disconcordance in our study. The 
cloning of HEV and the availability of EIA ´sand GST fusion protein for detection for detection 
of anti-HEV have created a major breakthrough in our understanding of epidemiology and the 
clinical course of hepatitis E. However, it must be realized that the current diagnostic assays 
for hepatitis E are sub-optimal. False positive and false negative results may occur, as was 
the case in this study.  
Although, there is a high degree of homology among HEV sequences from Pakistani and the 
Burmese isolates, the homology between Mexican and Burmese isolates is less.(Purcell et al, 
1998). Thus, EIA that utilize HEV antigens from one ORF or one isolate my yield negative 
results. In all these studies in which multiple HEV antigens in both ORF2 and ORF3 from 
Burmese and Mexican isolates were used, the detection rate for individual antigens from 0 to 
100% among the reactive samples. (Krawczynski et al. 1999). Comparative studies with HEV 
antigens from other isolates have not  been conducted. However, it is obvious that multiple 
HEV antigens from more than one isolate have to be incorporated into  anti-HEV EIA´s for the 
diagnosis for hepatitis E in diverse geographical areas (Mast et al, 1998). There is less 
information on the specificity of the current anti-HEV assays. Confirmatory tests for HEV 
infection has to be developed. Direct comparison between the reactivity with recombinant 
HEV antigens and the corresponding synthetic peptides showed that smaller proportion of 
healthy subjects reacted against the synthetic peptides in the IgG anti-HEV assays, 
suggesting that EIA using recombinant antigens may give false positive results. (Seriwatana 
et al, 2002). Similar comparison has to be conducted on the IgM anti-HEV EIA´s as reviewed 
in this study. Hepatitis E - Virus (HEV): 
Comparative evaluation of IgG antibody assays in a low-endemicity setting 
 
  Page 67 
3.5.4 Evaluation  of Abbott EIA Versus DSL ELISA  
The results of serologic tests for hepatitis E virus have varied widely from laboratory to 
laboratory, making interpretation of seroepidemiologic studies difficult. 
The present comparison of tests for anti-HEV is first to make a detailed examination of the 
utility of the many gene products which have been utilized for assays for anti-HEV .In our study 
we compared the reactivity of anti-HEV IgG in both assays Abbot EIA and DSL ELISA. We 
observed a concordance of 54% and a disconcordance of 13,6%. The results of this test 
clearly showed that  tests for anti-HEV based upon expressed ORF2 were more sensitive for 
detecting anti-HEV than were tests based upon antigens derived from ORF3 (Ghabrah et al, 
1998). This was true for both IgG anti-HEV and IgM anti-HEV. The poorer showing of ORF3- 
based tests may result from a combination of a less vigorous immune response to this small 
protein and a shorter half-life of antibodies to ORF3. We observed a wide range of sensitivity 
and specificity as shown in our results 54% concordance. The reasons for the discrepancy 
between both  assays are not clear. We probably believed , however, that these assays of the 
IgG class antibodies often missed remote HEV infections because of their low sensitivity in 
areas where hepatitis E is not endemic. Thus, a reliably sensitive and specific antibody assay 
is needed to conduct accurate epidemiological studies. Further reason for a wide range of 
discrepant results might be due to low-titre antibodies having been destroyed by repeated 
freezing and thawing in later study. Another possible explanation for decline detectability of 
IgG antibodies in these assays might be sequence variations among the different HEV 
genotypes. Specifically, the choice and size of antigen appears to make a significant 
difference in the results (Nishizawa et al, 2003). Finally a poor host immune response to HEV 
infection might also account for undetectable IgG anti-HEV optical density values.  Hepatitis E - Virus (HEV): 
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4  Discrepancies 
These findings have raised the questions about the sensitivity and the specificity of the 
currently available test for anti-HEV as well as questions about how long anti-HEV can be 
detected after infection .For instance, Goldsmith et al 1992 found out that IgG anti-HEV could 
be detected for less than 6 months in about half tested children who were convalescing from 
hepatitis E but Bryan et al 1994 found all of 33 convalescent adults to be positive 20 months 
after infection and anti-HEV has been detected by Kharoo et al 1993 as long as 14 years 
after clinical hepatitis E in India. Many of these unexpected results and discrepancies can be 
ascribed to  differences in assays for the anti-HEV. Specifically, the choice and the size of the 
antigen, appears to make a significant difference in the results. Assays for anti-HEV based 
on antigenic epitopes  of the ORF-3 gene product detect a lower prevalence of anti-
prevalence suggesting these antibodies directed against epitopes of the products of ORF-2. 
This problems is compounded by a greater genetic heterogeneity of ORF-3 genes, possibly 
leading to serologic differences among different HEV strains, and diminished sensitivity of 
assays based upon only one or a limited number of genetic variants of the ORF-3 product. In 
contrast, gene products of ORF-2 are more genetically homogeneous and measure anti-HEV 
that remains detectable for years. Clinical disease data suggest that hepatitis E virus (HEV) 
is a  pathogen  with a restricted geographical range. The purpose of our study was to 
compare hepatitis E assays: 
Abbott EIA, Mikrogen Westernblot, Genelabs and DSL ELISA (a Prototype ) of their 
sensitivity and specificity and to evaluate their abilities to diagnose hepatitis E with acute 
sporadic viral  hepatitis and convalescent phase sera in a routine test at the Virology 
Department of Frankfurt University clinics between 1998-2001. Hepatitis E - Virus (HEV): 
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Possible explanations of discrepances can be allude to the following reasons: 
-  a low sensitivity of available assays? 
-  specifically choice and size of HEV antigen? 
-  duration of antibody persistence ? 
-  subclinical (anicteric ) HEV infection ? 
-  a cross-reactivity with a different agent ? 
-  a non-specificity leading to false positivity ? 
-  infection with non-pathogenic HEV strain, e.g. swine HEV or zoonotic strain ? 
-  and a combination of any of the above? Hepatitis E - Virus (HEV): 
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4.1  Problems and Conclusions 
The study of  Hepatitis E has been an instructive story recent advancements in medical 
science. Substantial progress has been made in a short period of time through both 
epidemiological studies and basic research, which has relied on modern cloning and 
recombinant technology. New tools have clearly accelerated the pace of research. Within less 
than two decades of the discovery of HEV, the major epidemiological features of this unique 
pathogen  have been described, serologic tests have been developed, and a vaccine has 
been evaluated in an initial clinical trial. (Yabough et al., 1999). 
 Nevertheless, there are still may mysteries about the epidemiology, pathogenesis, and 
immune response of HEV infection. The unknown aspects of hepatitis E could have a major 
impact on vaccine development and use.. However, vaccine research could be also illuminate 
the immunologic characteristics of this unique infectious disease. The development of an 
animal model of HEV infection in the laboratory would aid research efforts substantially. It is 
likely that a HEV vaccine will be developed that provides at least short-term protection from 
disease. 
Who will make and buy this vaccine?  Because of incidence of acute  HEV infection among 
travellers from developed world to endemic countries has been estimated to be less than one 
million (Piper-Jenk et al 2000), the  market for this vaccine in non endemic countries will be 
limited.(Shlim et al., 2000).  Pregnant women living in endemic regions may derive the 
greatest benefit from an effective HEV vaccine. Hepatitis E - Virus (HEV): 
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Our study has led us to draw the following conclusions: 
-  we observed a high rate of divergent results using three commercially available and 
one ´´prototype´´HEV IgG antibody assays on sera reactive by the Abbott EIA 
-   This is in agreement with previous studies that used variety of different assays. 
-  The interpretation of HEV antibody test results in ´´low-risk´´ populations remains 
problematic 
-   A ´´grey zone´´ needs to be defined as low-level reactivity is common and mostly 
cannot be confirmed by additional tests but is probably non-specific. Hepatitis E - Virus (HEV): 
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5  Summary 
Hepatitis E virus (HEV) is a positive-stranded RNA virus with a 7.2 kb genome that is capped 
and polyadenylated. The virus is currently unclassified : the organisation of the genome 
resembles that of the Caliciviridae but sequence analyses suggest that it is more closely 
related to the Togaviridae. HEV is an enterically transmitted virus that causes both epidemics 
and sporadic cases of acute hepatitis in many countries of Asia and Africa but only rarely 
causes disease in more industrialised countries. Initially the virus was believed to have a 
limited geographical distribution. However, serological studies suggest that that HEV may be 
endemic also in the United states and Europe even though it infrequently causes overt 
disease in these countries. Many different animal species  worldwide recently have been 
shown to have antibodies to HEV suggesting that hepatitis E may be zoonotic. Although two 
related strains have been experimentally transmitted between species, direct transmission 
from animal to a human has not been documented. 
Our main objective in this study is to evaluate the suitability of current available HEV antibody 
assays for use in  low-endemicity areas such as in  Germany. 
Methods: We selected sera on the basis of at least borderline reactivity in the routinely used 
Abbot EIA. Most were tested as part of routine screening of long-term expatriates in endemic 
countries. The following assays (recombinant antigens : ORF2 and ORF3) were used: Abbot 
EIA, Genelabs ELISA, Mikrogen recomBlot and a `Prototype´ DSL-ELISA. Hepatitis E - Virus (HEV): 
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We observed a wide range of sensitivity ( average of 56.8%) and specificity ( an average of 
61.4%) in these used assays. These results implies that , these assays might be unreliable for 
detection of HEV infection in areas where hepatitis E is not endemic. However, most anti-
HEV assays  have not been correlated with the HEV RNA determined by  reverse 
transcription. Many of these unexpected results and discrepancies can be alluded to the 
following reasons: 
I.  The choice and the size of the HEV antigen. 
II.  Duration of the antibody persistence 
III.  A cross reactivity with different agent 
IV.  Due to geographic species 
V.  A low sensitivity of the available assays. 
VI.  And infection with non-pathogenic HEV strain. (zoonotic strain?).  
 We therefore suggest that, further studies will be required to improve the  sensitivity and 
specificity of the available commercial assays on the market. 
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8  Zusammenfassung 
Das Hepatitis E Virus (HEV) ist ein RNA+ - Virus mit einem 72 kb Genom, das behüllt und 
polyadenyliert ist. Das Virus ist momentan nicht eindeutig klassifiziert. Die Organisation des 
Genoms ähnelt der der Caliciviridae, aber Sequenzanalysen deuten darauf hin, dass es 
näher mit den Togaviridae verwandt ist. HEV wird enteral übertragen und verursacht sowohl 
Epidemien wie auch sporadisch auftretende Fälle von akuter Hepatitis in vielen Ländern 
Asiens und Afrikas, aber nur vereinzelt Erkrankungen in den industrialisierten Ländern. 
Anfänglich glaubte man, das Virus besitze eine nur begrenzte geographische Ausbreitung. 
Serologische Studien lassen hingegen vermuten, dass HEV auch in den USA und Europa 
endemisch sein könnte, auch wenn es nur selten ansteckende Krankheiten in diesen Ländern 
hervorruft. In vielen verschiedenen Tierspezies weltweit konnten HEV-Antikörper 
nachgewiesen werden, so dass vermutet werden kann, bei der  Hepatitis E handele es sich 
um eine Zoonose.  Obwohl zwei verwandte Stränge experimentell zwischen zwei Spezies  
übertragen wurden, ist bislang keine direkte Übertragung vom Tier auf den Menschen 
nachgewiesen. 
 
Das Ziel dieser Studie liegt darin, die Anwendbarkeit gebräuchlicher HEV Antikörper Assays 
für den Gebrauch in Niedrigendemiegebieten  wie Deutschland zu evaluieren. 
 
Methoden: Wir haben Sera ausgewählt, die im routinemässig verwendeten Abbott E IA 
mindestens grenzwertig reagiert haben. Die meisten wurden im Rahmen des 
Routinescreenings von Personen nach Langzeitauslandsaufenthalten (deutsche 
Entwicklungshelfer)  in Endemiegebieten durchgeführt.  
Folgende Assays (Rekombinante Antigene ORF2 und ORF3) wurden verwendet: Abbot EIA, 
Genelabs ELISA, Mikrogen recomBlot und ein „Prototyp“ DSL-ELISA. 
 
Wir beobachteten eine große Spannweite in der Sensitivität (im Durchschnitt  56,8%) und 
Spezifität (im Durchschnitt  61,4%) bei den verwendeten Assays. Diese Ergebnisse legen 
den Schluss nahe, dass diese Assays möglicherweise für den Nachweis einer HEV-Infektion 
in Gebieten, in denen HEV nicht endemisch ist, unzuverlässig sind. Bislang ist die Mehrzahl 
der HEV-Assays nicht mit dem Nachweis durch Reverse Transkription  hergestellter HEV-
RNA korreliert worden. 
Viele dieser unerwarteten und diskrepanten Ergebnisse  können den folgenden  Gründen 
zugeschrieben werden: 
 
I  der Auswahl des HEV-Antigens und dessen Größe 
II  der Dauer der Antikörper-Persistenz 
III  der Kreuzreaktivität mit verschiedenen Agentien 
IV  dem geographischen Subtyp 
V   einer niedrigen Sensitivität der verfügbaren Assays 
VI  und einer Infektion mit einem nicht-pathogenen HEV Strang (zoonotische 
Übertragung?). 
 
Aus diesen Gründen hielten wir weiterführende Studien mit dem Ziel, die Sensitivität und 
Spezifität der am Markt verfügbaren Assays zu verbessern, für sinnvoll.  Hepatitis E - Virus (HEV): 
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